BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Bayer Yakuhin Ltd. Files Anti-Cancer Drug Nexavar(R) For The Treatment Of Advanced Renal Cell Carcinoma


6/29/2006 2:19:11 PM

Tokyo, June 29, 2006 (JCN) - Today, Bayer Yakuhin Ltd. submitted a marketing application of an orally available anti-cancer drug, Nexavar(R) (sorafenib, BAY 43-9006) 200 mg tablet for the treatment of Advanced Renal Cell Carcinoma (RCC), which was developed by Bayer HealthCare AG (Germany) and Onyx Pharmaceuticals, Inc. (USA), to the Pharmaceuticals and Medical Devises Agency (PMDA) in Japan. Nexavar(R) was approved by FDA in December 2005 for the first time in the world and is now on the US market. Also it was approved by the regulatory authorities of Switzerland, Mexico, Chile, Brazil and South Korea. In EU, the application was submitted to EMEA in September 2005.

Read at JCN Newswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->